Lundbeck head of R&D: "We have cleared the way for opportunity"

After three years leading Lundbeck’s research and development division, Johan Luthman feels that the company is poised to strike, should chance present itself. ”Luck is an important part of our industry,” he says.

Photo: Torben Klint/Ritzau Scanpix

With a résumé listing some of the top positions at firms like Eisai, Merck, and Astrazeneca, 61-year-old Swedish national Johan Luthman can hardly be blamed for coming to the Danish pharmaceutical industry with a sense pride, and perhaps limited respect for where he was going, when he joined Lundbeck as head of research and development three years ago.

”I really hadn’t expected what I saw when I arrived in Copenhagen. I was very positively surprised, and that’s where my arrogance came into play. I had thought, ’What can Copenhagen offer that Boston and Cambridge cannot?’ But I have to say that I quickly realized that – wow – something extraordinary is happening here,” says Luthman, who ascribes a large part of the credit to Danish fund owners.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today